Beta Laboratories reported the following footnote related to its convertible debentures. 2.75% series A and B debentures During the third quarter of fiscal 2016, we sold 2.75% Series A Convertible Senior Debentures and 2.75% Series B Convertible Senior Debentures for an aggregate amount of $1.6 billion, net of the underwriters' discount and related fees and expenses of $46 million. The debentures were issued at a price of $1,000 per debenture and were issued under our universal shelf. The debentures rank equal in priority with all of the existing and future unsecured and unsubordinated indebtedness and senior in right of payment to all of the existing and future subordinated indebtedness. The terms governing the debentures limit our ability to create liens, secure certain indebtedness and merge with or sell substantially all of our assets to another entity. The debentures are convertible into shares of common stock only if (1) the average sale price of our common stock is at least equal to 120% of the applicable conversion price, (2) the average trading price of the debentures is less than 97% of the product of the sale price of the common stock and the conversion rate, (3) the debentures have been called for redemption by us or (4) certain specified corporate actions occur. How will Beta Laboratories account for the conversion of the 2.75% debentures, if and when conversion occurs? Specifically, will Beta Laboratories recognize any gain or loss related to conversion? a. Gain or loss is recorded for unamortized discount or premium at time of conversion b. Gain or loss is recorded as difference between market value of stock and book value of debentures at time of conversion c. Gain or loss is recorded as difference between market value of stock and market value of debentures at time of conversion d. No gain or loss from conversion is reported
Beta Laboratories reported the following footnote related to its convertible debentures. 2.75% series A and B debentures During the third quarter of fiscal 2016, we sold 2.75% Series A Convertible Senior Debentures and 2.75% Series B Convertible Senior Debentures for an aggregate amount of $1.6 billion, net of the underwriters' discount and related fees and expenses of $46 million. The debentures were issued at a price of $1,000 per debenture and were issued under our universal shelf. The debentures rank equal in priority with all of the existing and future unsecured and unsubordinated indebtedness and senior in right of payment to all of the existing and future subordinated indebtedness. The terms governing the debentures limit our ability to create liens, secure certain indebtedness and merge with or sell substantially all of our assets to another entity. The debentures are convertible into shares of common stock only if (1) the average sale price of our common stock is at least equal to 120% of the applicable conversion price, (2) the average trading price of the debentures is less than 97% of the product of the sale price of the common stock and the conversion rate, (3) the debentures have been called for redemption by us or (4) certain specified corporate actions occur. How will Beta Laboratories account for the conversion of the 2.75% debentures, if and when conversion occurs? Specifically, will Beta Laboratories recognize any gain or loss related to conversion? a. Gain or loss is recorded for unamortized discount or premium at time of conversion b. Gain or loss is recorded as difference between market value of stock and book value of debentures at time of conversion c. Gain or loss is recorded as difference between market value of stock and market value of debentures at time of conversion d. No gain or loss from conversion is reported
Chapter1: Financial Statements And Business Decisions
Section: Chapter Questions
Problem 1Q
Related questions
Question
Transcribed Image Text:Beta Laboratories reported the following footnote related to its convertible debentures.
2.75% series A and B debentures During the third quarter of fiscal 2016, we sold
2.75% Series A Convertible Senior Debentures and 2.75% Series B Convertible
Senior Debentures for an aggregate amount of $1.6 billion, net of the underwriters'
discount and related fees and expenses of $46 million. The debentures were issued
at a price of $1,000 per debenture and were issued under our universal shelf. The
debentures rank equal in priority with all of the existing and future unsecured and
unsubordinated indebtedness and senior in right of payment to all of the existing and
future subordinated indebtedness. The terms governing the debentures limit our
ability to create liens, secure certain indebtedness and merge with or sell
substantially all of our assets to another entity. The debentures are convertible into
shares of common stock only if (1) the average sale price of our common stock is at
least equal to 120% of the applicable conversion price, (2) the average trading price
of the debentures is less than 97% of the product of the sale price of the common
stock and the conversion rate, (3) the debentures have been called for redemption by
us or (4) certain specified corporate actions occur.
How will Beta Laboratories account for the conversion of the 2.75% debentures, if and when
conversion occurs? Specifically, will Beta Laboratories recognize any gain or loss related to
conversion?
a. Gain or loss is recorded for unamortized discount or premium at time of conversion
b. Gain or loss is recorded as difference between market value of stock and book value of
debentures at time of conversion
c. Gain or loss is recorded as difference between market value of stock and market value of
debentures at time of conversion
d. No gain or loss from conversion is reported
Expert Solution
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
This is a popular solution!
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
Recommended textbooks for you
Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,
Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,
Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,
Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,
Horngren's Cost Accounting: A Managerial Emphasis…
Accounting
ISBN:
9780134475585
Author:
Srikant M. Datar, Madhav V. Rajan
Publisher:
PEARSON
Intermediate Accounting
Accounting
ISBN:
9781259722660
Author:
J. David Spiceland, Mark W. Nelson, Wayne M Thomas
Publisher:
McGraw-Hill Education
Financial and Managerial Accounting
Accounting
ISBN:
9781259726705
Author:
John J Wild, Ken W. Shaw, Barbara Chiappetta Fundamental Accounting Principles
Publisher:
McGraw-Hill Education